News and Events
ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic
RANCHO CORDOVA, Calif., Sept 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The multi-pronged … Continued
ThermoGenesis Distributes FDA Emergency Use Authorized COVID-19 Antibody Test Kit. What Does it Mean?
ThermoGenesis recently announced it has entered into a supply agreement with Biohit Healthcare to distribute its COVID-19 Antibody Test Kit. This agreement is significant because Biohit Healthcare has already received Emergency Use Authorization from the U.S. Food and Drug Administration. What is Emergency Use Authorization? The U.S. Food and Drug Administration (FDA) plays an … Continued
ThermoGenesis Holdings to Participate in Investor Conferences in September
RANCHO CORDOVA, Calif., Aug. 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management’s participation in the following investor conferences in September. September 1-4: LD Micro 500. Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis, will present … Continued
The Technology Behind Cord Blood Processing: AXP® II System
Cells are the basic building blocks of all biological life. Within these cells are small sections of proteins in DNA that possess all our genetic information, called genes. According to The Human Genome Project, it’s estimated that humans have between 20,000 and 25,000 genes. These genes all carry vital instructions for making proteins, which in … Continued
Convalescent Plasma Therapy for Coronavirus Patients
As scientists around the world work tirelessly to design new medicines for COVID-19, doctors have turned to convalescent plasma therapy to see if it could be a viable treatment option for coronavirus. While conservative measurements place the widespread availability of a coronavirus vaccine around somewhere in early 2021, convalescent plasma may potentially serve as a … Continued
ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2020 and Provides Corporate Update
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 14, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the second quarter ended June 30, 2020 … Continued
ThermoGenesis Enters Into Supply Agreement with New EUA Approved COVID-19 Antibody Test Manufacturer; Marketing to Begin on August 17, 2020
RANCHO CORDOVA, Calif., August 13, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced that on August 12, the Company entered into a supply agreement with BioHit Healthcare (Hefei) Co., Ltd. to market, under the ThermoGenesis brand, its SARS-CoV-2 IgM/IgG Antibody … Continued
ThermoGenesis Holdings to Delay Second Quarter 2020 Earnings Release and Conference Call Until Friday August 14, 2020
RANCHO CORDOVA, Calif., Aug. 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its second quarter earnings release and conference call for the quarter ended June 30, 2020, previously scheduled for Wednesday, August 12, … Continued